ClinicalTrials.gg
Active, not recruitingNCT05081193Updated Sep 29, 2026Results posted

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

A Phase 2 interventional study of Testosterone Undecanoate and Enzalutamide in Prostate Cancer, Castration-resistant Prostate Cancer and Metastatic Castration-resistant Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Active, not recruiting at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

How we know

Updated Sep 29, 2026Now Active, not recruitingResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
107th of 125
15 · median 52
Started
2022
with 5 others
Phase 2
65 of 125
8 open now
Primary completion
2025-08
later than 11 of 37 live
Registered
108th of 125
by date
Lead sponsor
7 of 125
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 107th largest by enrollment, is one of 6 that started in 2022, is one of 65 in phase 2, reaches primary completion later than 11 of the 37 other live ones, and was the 108th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response. This injection regimen was given as one dose of 400mg injection every 28 days, which initially produces high serum testosterone levels but these levels drop to a varying degree in some men over the 28-day cycle.

In this 30 patient trial will analyze the effects of oral testosterone therapy in men with metastatic castrate resistant prostate cancer taken on a schedule of seven days of oral testosterone therapy followed by seven days of no therapy for a twenty-eight day cycle. This therapy will be given for three 28 day cycles consecutively followed by radiographic scans to evaluate the metastatic disease. Patients will be allowed to continue on this therapy until the patients show signs of radiographic progression. If the patients show signs of radiographic progression after the first three cycles, the patients will stop taking the oral testosterone therapy and begin taking enzalutamide therapy. Enzalutamide therapy will be taken for three 28 day cycles, then radiographic scans will be taken. If there are no signs of radiographic progression, patients can continue to take enzalutamide therapy for an additional 3 cycles while on study. Patients with continued PSA or objective response will come off study but continue on enzalutamide as standard of care therapy.

This study will help the investigators to understand if treating these men with the highest FDA approved dose of oral testosterone therapy will achieve similar and sustained high levels of serum testosterone that will produce similar or enhanced therapeutic response to the therapy when compared to the serum testosterone levels found in the previous injection therapy trials.

Read the detailed description

Metastatic prostate cancer is a highly significant disease that claims the lives of approximately 30,000 American men each year. Androgen Deprivation Therapy (ADT) is initially very effective but is never curative as all men eventually develop castrate resistant prostate cancer (CRPC). A major factor driving resistance is the ability of prostate cancer (PCa) cells to adapt to the chronic low androgen conditions by upregulating androgen receptor (AR) activity through overexpression, gene amplification and expression of truncated, transcriptionally active AR variants that lack the ligand-binding domain. Persistent signaling through AR makes CRPC sensitive to more potent inhibition of AR by abiraterone acetate or second generation anti-androgens such as enzalutamide. Yet these therapies have a limited duration of benefit prior to development of resistance, often through further increase in AR levels.

While this marked upregulation of AR can drive resistance, the investigators have demonstrated that it also creates a therapeutic vulnerability to exposure to high levels of androgen. However, the investigators have also found that sustained exposure of CRPC to supraphysiological levels of androgens results in downregulation of AR and acquired resistance to this therapy. Therefore the investigators have developed a therapy called Bipolar Androgen Therapy (BAT) in which testosteronecypionate 400 mg IM is administered every 28 days to result in cycling from supraphysiological (>1500 ng/dL) to near-castrate levels. The rationale for cycling was that high serum T would kill high AR expressing CRPC while low serum T would prevent adaptation to high T and kill low AR expressing CRPC.

To date the investigators have treated approximately 250 men with BAT across four completed studies in asymptomatic men with CRPC. The key findings have been that BAT: (a) could be safely administered; (b) did not produce symptomatic disease progression; (c) produced sustained PSA and objective responses in approximately 30-40% of patients; (d) re-sensitized and prolonged response of patients to subsequent antiandrogen therapy. While ADT for advanced PCa often produces debilitating sexual and metabolic side effects, another highly significant feature of this approach is that BAT can make men feel remarkably better by decreasing fatigue, increasing physical activity and restoring libido and sexual function. BAT also produced favorable effects on body composition by increasing skeletal muscle mass and decreasing subcutaneous and visceral fat. Thus, incorporation of BAT into the treatment paradigm has the potential to improve the quality of life and well-being of PCa patients and minimize the morbidity from the metabolic sequelae produced by androgen ablative therapies.

The studies performed to date demonstrate the safety and efficacy of high dose T in men with metastatic CRPC who are progressing on androgen ablative therapy. The investigators' limited data suggests that high serum levels of T may be required for clinical response. This high level has is achieved through intramuscular (IM) administration of testosterone cypionate at the highest FDA-approved dose of 400 mg every 28 days. This regimen initially produces high serum T levels but these levels drop to a varying degrees approaching near castrate levels in some men over a 28-day cycle. To date, the investigators have not tested whether more rapid cycling of serum T would produce similar or improved therapeutic response in this patient population. Additional issues with IM testosterone are (1) it requires patients to come to hospital every 28 days for injection, (2) has highly variable pharmacokinetics, (3) can cause physical discomfort from IM injections.

Recently two novel oral testosterone (OT) agents were developed for the treatment of male hypogonadism. Historically, an oral option for testosterone replacement therapy was unavailable because of risks of liver toxicity, including cholestasis and jaundice, associated with earlier developed 17-alpha-alkylated oral analogs. These novel oral agents feature specialized formulations that avoid adverse hepatic effects. In clinical trials, both oral agents produced no significant adverse effects on liver function tests. The investigators have formed a collaborative partnership with Clarus Therapeutics, the makers of Jatenzo, an oral lipoprotein-coated testosterone undecanoate (OT) formulation that was FDA-approved in December 2019 as T-replacement therapy. Published pharmacokinetic data demonstrate that OT can produce supraphysiologic serum T levels when administered at the highest FDA-approved dose. Therefore, the investigators' hypothesis is that OT, given at the highest FDA approved dose, will achieve more homogeneous and sustained supraphysiologic levels of serum T that will produce similar or enhanced therapeutic response. To avoid adaptation of CRPC to this sustained level of T, the investigators will utilize a dosing schedule of 1 week-on, 1 week-off.

03

Conditions studied

  • Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Oral Testosterone Therapy
  • Enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has the ability to understand and willingness to sign a written document.
  • Patient is a male aged 18 years or older.
  • Patient has -confirmed adenocarcinoma of the prostate
  • Patient has an (ECOG) performance status of ≤2 (as defined in Appendix A: Performance Status Criteria;
  • Patient has evidence of , by CT scan. Measurable disease is defined by 1.1 as at least one measurable lesion ≥10mm by CT scan
  • Patient is progressing on continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist)
  • Patient has documented castrate level of serum testosterone (\<50 ng/dl)
  • Patient is progressing on luteinizing hormone-releasing hormone (LHRH) agonist/antagonist plus anti-androgen or abiraterone for CSPC. (Note: Must be off anti-androgen or abiraterone for 4 weeks prior to first treatment with OT.) LHRH (luteinizing hormone-releasing hormone)
  • Patient has had prior docetaxel for CSPC. Note: Docetaxel is permitted if ≤ 6 doses were given in conjunction with androgen deprivation therapy and >6 months since last dose of docetaxel. (CSPC-castrate sensitive prostate cancer)
  • Patient is currently taking prednisone and cannot be weaned entirely off. Note: Patient's dose must be maintained on lowest stable dose that relieves symptoms. Patient is receiving prednisone in conjunction with abiraterone acetate must be weaned off prednisone if possible prior to starting OT.
  • Patient has had a rising PSA on two successive measurements at least two weeks apart.
  • Patient agrees to continue on castrating therapy throughout OT treatment.
  • Patient's screening lab values are within the following parameters:

    1. (ANC) ≥ 1500 cells/mm3 (1.5 ×109/L)
    2. count ≥ 100,000 platelet/mm3 (100 ×109/L)
    3. ≥ 9 g/dL
    4. Serum creatinine \< 2.5 times
    5. \< 2.5 times institutional upper limit of normal (ULN)
    6. (AST) and Alanine Aminotransferase (ALT) \< 2.5 times ULN
  • Patient has had surgery, has completed at least 4 weeks of recovery and has no persistent toxicity > grade 1.

Exclusion criteria

Exclusion Criteria:

  • Patient has pain due to prostate cancer requiring opioid analgesics.
  • Patient has had prior treatment with any agent for metastatic castration-resistant prostate cancer. (Includes docetaxel, cabazitaxel, anti-androgen, abiraterone, or agents)
  • Patient requires urinary catheterization for voiding due to obstruction secondary to prostatic enlargement thought to be due to prostate cancer or benign prostatic hyperplasia. Note: Patients with indwelling catheter/suprapubic catheter to relieve obstruction are eligible.
  • Patient has evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, epidural spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction).
  • Patient has evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, epidural spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction).
  • Patient has active uncontrolled infection, such as /AIDS or chronic or untreated chronic .
  • Patient has had prior history of a thromboembolic event within the past two years and not currently on systemic anticoagulation.
  • Patient is on Coumadin. Note: If anticoagulation therapy is mandatory, patient must be switched to an alternative medication) Patients receiving anticoagulation therapy with warfarin, rivaroxaban or apixaban are not eligible for study. [Patients on enoxaparin or edoxaban are eligible for study. Patients on warfarin, rivaroxaban or apixaban, who can be transitioned to enoxaparin prior to starting study treatments, will be eligible.
  • Patient has hematocrit >50%, untreated severe obstructive sleep apnea, uncontrolled or poorly controlled heart failure [per Endocrine Society Clinical Practice Guidelines].
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Oral Testosterone Therapy given until radiographic progression followed by Enzalutamide Therapy

    Oral Testosterone Therapy-396 mg given twice per day on days 1-7 and 15-21 of a 28 day cycle until radiographic progression. After a 21 day washout period, Enzalutamide therapy given at 160 mg once daily will be taken for a maximum of 6 cycles while on study.

    Drug: Testosterone Undecanoate · Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate of Oral Testosterone Undecanoate (CT Scan)

    Radiographic responses to Oral Testosterone therapy using CT scan measurements. Radiographic progression is assessed by RECIST (Response Evaluation Criteria in Solid Tumors). Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions.

    Time frame: Up to 2 years post Oral Testosterone

Secondary outcomes

  1. PSA50 Response to Oral Testosterone Therapy

    Number of participants with PSA50 response to Oral Testosterone therapy defined as at least a 50% decline in Prostate Specific Antigen (PSA) from baseline value.

    Time frame: Up to 2 years post Oral Testosterone

  2. Time to PSA Progression While on Oral Testosterone

    Number of months from baseline until PSA progression

    Time frame: Up to 2 years post Oral Testosterone

  3. Time to Clinical or Radiographic Progression While on Oral Testosterone

    Number of months from baseline until radiographic or clinical progression, whichever comes first. Radiographic progression is assessed by Response Evaluation Criteria in Solid Tumors (RECIST) and Prostate Cancer Working Group 3 (PCWG3) criteria. Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions. Per PCWG3 criteria, radiographic progression is defined as ≥ 20% sum of the longest diameter of target lesions, or ≥ 2 new lesions on bone scan from baseline. Clinical progression is defined as new spinal cord or nerve root compression, new pathologic fracture or use of opioid analgesics for cancer-related pain.

    Time frame: Up to 2 years post Oral Testosterone

  4. PSA50 Response to Enzalutamide Therapy

    Number of participants with PSA50 response to enzalutamide therapy defined as at least a 50% decline in Prostate Specific Antigen (PSA) from baseline value.

    Time frame: Up to 2 years post Enzalutamide

  5. Objective Response Rate of Enzalutamide Therapy (CT Scan)

    Radiographic responses to Enzalutamide therapy using CT scan measurements after 3 cycles and after 6 cycles of therapy. Radiographic progression is assessed by RECIST (Response Evaluation Criteria in Solid Tumors) criteria ). Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions.

    Time frame: Up to 2 years post Enzalutamide

  6. Trough Testosterone Level

    Mean trough testosterone level (ng/dL) measured within 24, 48, 72 or 96 hours after cycle 1 day 7 dose of oral testosterone therapy

    Time frame: Up to 96 hours after cycle 1 day 7 dose

  7. PBMC Immunologic and Metabolic Phenotype

    Phenotype of peripheral blood mononucleated cell (PBMC) as defined by number of cluster of differentiation 4 (CD4) Tcells, cluster of differentiation 8 (CD8) Tcells, FOXP3+ Treg cells, B cells, Natural Killer (NK) cells, monocytes, dendritic cells, and myeloid derived suppressor cells. PBMCs will be immunophenotyped using multiparameter flow cytometry.

    Time frame: 2 years

  8. Change in Quality of Life as Assessed by The-FACIT-Fatigue Questionnaire

    The Functional Assessment of Chronic Illness Therapy - Fatigue has a score range of 0-52 with higher scores indicating better quality of life.

    Time frame: Up to 2 years post Oral Testosterone

  9. Change in Quality of Life as Assessed by the- Short Form 36 (SF-36) Questionnaire

    All questions are scored on a scale from 0 to 100. The total score from all of the questions answered is divided by the total number of the questions answered yielding a global score from 0-100 with 100 representing the highest level of functioning possible.

    Time frame: Up to 2 years post Oral Testosterone

  10. Safety of Trial Therapy as Assessed by Adverse Event Reporting

    Safety as assessed by related adverse event reporting. Grading of adverse events will be done by utilizing the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Determination of relationship of the adverse event to the study procedures or study drug will be performed by the PI using the standard attribution terminology (e.g. unrelated, possibly related, etc.).

    Time frame: Up to 28 days post all treatment

  11. Tolerability of Trial Therapy as Assessed by Adverse Event Reporting

    Tolerability as assessed by related adverse event reporting. Grading of adverse events will be done by utilizing the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Determination of relationship of the adverse event to the study procedures or study drug will be performed by the PI using the standard attribution terminology (e.g. unrelated, possibly related, etc.).

    Time frame: Up to 28 days post all treatment

  12. Time to PSA Progression While on Enzalutamide

    Number of weeks from start of enzalutamide treatment until PSA progression.

    Time frame: Up to 2 years post enzalutamide

  13. Time to PSA Progression While on Enzalutamide From Start of Oral Testosterone Therapy

    Number of weeks from start of oral testosterone therapy until PSA progression while on enzalutamide treatment.

    Time frame: Up to 2 years post all treatment

07

Results

Posted Sep 29, 2026

Participant flow

Intervention 1 (1 Year)
Participant flow — Intervention 1 (1 Year)
MilestoneOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Started15
Completed12
Not completed3
Withdrew: Did not start treatment2
Withdrew: Withdrawal by subject1
Washout (21 Days)
Participant flow — Washout (21 Days)
MilestoneOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Started11
Completed11
Not completed0
Intervention 2 (90 Days)
Participant flow — Intervention 2 (90 Days)
MilestoneOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Started10
Completed10
Not completed0

Outcome measures

PrimaryObjective Response Rate of Oral Testosterone Undecanoate (CT Scan)

Radiographic responses to Oral Testosterone therapy using CT scan measurements. Radiographic progression is assessed by RECIST (Response Evaluation Criteria in Solid Tumors). Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions.

Time frame:
Up to 2 years post Oral Testosterone
Reported as:
Count of participants · Participants
Objective Response Rate of Oral Testosterone Undecanoate (CT Scan)
ParticipantsOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Objective Response Rate of Oral Testosterone Undecanoate (CT Scan)2
SecondaryPSA50 Response to Oral Testosterone Therapy

Number of participants with PSA50 response to Oral Testosterone therapy defined as at least a 50% decline in Prostate Specific Antigen (PSA) from baseline value.

Time frame:
Up to 2 years post Oral Testosterone
Reported as:
Count of participants · Participants
PSA50 Response to Oral Testosterone Therapy
ParticipantsOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
PSA50 Response to Oral Testosterone Therapy4
SecondaryTime to PSA Progression While on Oral Testosterone

Number of months from baseline until PSA progression

Time frame:
Up to 2 years post Oral Testosterone
Reported as:
Median · months
Time to PSA Progression While on Oral Testosterone
monthsOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Time to PSA Progression While on Oral Testosterone4.7 (1.87 to 7.43)
SecondaryTime to Clinical or Radiographic Progression While on Oral Testosterone

Number of months from baseline until radiographic or clinical progression, whichever comes first. Radiographic progression is assessed by Response Evaluation Criteria in Solid Tumors (RECIST) and Prostate Cancer Working Group 3 (PCWG3) criteria. Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions. Per PCWG3 criteria, radiographic progression is defined as ≥ 20% sum of the longest diameter of target lesions, or ≥ 2 new lesions on bone scan from baseline. Clinical progression is defined as new spinal cord or nerve root compression, new pathologic fracture or use of opioid analgesics for cancer-related pain.

Time frame:
Up to 2 years post Oral Testosterone
Reported as:
Median · months
Time to Clinical or Radiographic Progression While on Oral Testosterone
monthsOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Time to Clinical or Radiographic Progression While on Oral Testosterone5.6 (2.8 to NA)
SecondaryPSA50 Response to Enzalutamide Therapy

Number of participants with PSA50 response to enzalutamide therapy defined as at least a 50% decline in Prostate Specific Antigen (PSA) from baseline value.

Time frame:
Up to 2 years post Enzalutamide
Reported as:
Count of participants · Participants
PSA50 Response to Enzalutamide Therapy
ParticipantsOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
PSA50 Response to Enzalutamide Therapy7
SecondaryObjective Response Rate of Enzalutamide Therapy (CT Scan)

Radiographic responses to Enzalutamide therapy using CT scan measurements after 3 cycles and after 6 cycles of therapy. Radiographic progression is assessed by RECIST (Response Evaluation Criteria in Solid Tumors) criteria ). Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions.

Time frame:
Up to 2 years post Enzalutamide
Reported as:
Count of participants · Participants
Objective Response Rate of Enzalutamide Therapy (CT Scan)
ParticipantsOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Objective Response Rate of Enzalutamide Therapy (CT Scan)5
SecondaryTrough Testosterone Level

Mean trough testosterone level (ng/dL) measured within 24, 48, 72 or 96 hours after cycle 1 day 7 dose of oral testosterone therapy

Time frame:
Up to 96 hours after cycle 1 day 7 dose
Reported as:
Median · ng/dL
Trough Testosterone Level
ng/dLOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Trough Testosterone Level471.5 ± 229
SecondaryPBMC Immunologic and Metabolic Phenotype

Phenotype of peripheral blood mononucleated cell (PBMC) as defined by number of cluster of differentiation 4 (CD4) Tcells, cluster of differentiation 8 (CD8) Tcells, FOXP3+ Treg cells, B cells, Natural Killer (NK) cells, monocytes, dendritic cells, and myeloid derived suppressor cells. PBMCs will be immunophenotyped using multiparameter flow cytometry.

Time frame:
2 years

Results for this outcome have not been posted.

SecondaryChange in Quality of Life as Assessed by The-FACIT-Fatigue Questionnaire

The Functional Assessment of Chronic Illness Therapy - Fatigue has a score range of 0-52 with higher scores indicating better quality of life.

Time frame:
Up to 2 years post Oral Testosterone
Reported as:
Mean · score on a scale
Change in Quality of Life as Assessed by The-FACIT-Fatigue Questionnaire
score on a scaleOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Change in Quality of Life as Assessed by The-FACIT-Fatigue Questionnaire-0.333 ± 5.39
SecondaryChange in Quality of Life as Assessed by the- Short Form 36 (SF-36) Questionnaire

All questions are scored on a scale from 0 to 100. The total score from all of the questions answered is divided by the total number of the questions answered yielding a global score from 0-100 with 100 representing the highest level of functioning possible.

Time frame:
Up to 2 years post Oral Testosterone
Reported as:
Mean · score on a scale
Change in Quality of Life as Assessed by the- Short Form 36 (SF-36) Questionnaire
score on a scaleOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Change in Quality of Life as Assessed by the- Short Form 36 (SF-36) Questionnaire-1.6 ± 12.6
SecondarySafety of Trial Therapy as Assessed by Adverse Event Reporting

Safety as assessed by related adverse event reporting. Grading of adverse events will be done by utilizing the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Determination of relationship of the adverse event to the study procedures or study drug will be performed by the PI using the standard attribution terminology (e.g. unrelated, possibly related, etc.).

Time frame:
Up to 28 days post all treatment
Reported as:
Number · related events
Safety of Trial Therapy as Assessed by Adverse Event Reporting
related eventsOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Safety of Trial Therapy as Assessed by Adverse Event Reporting6
SecondaryTolerability of Trial Therapy as Assessed by Adverse Event Reporting

Tolerability as assessed by related adverse event reporting. Grading of adverse events will be done by utilizing the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Determination of relationship of the adverse event to the study procedures or study drug will be performed by the PI using the standard attribution terminology (e.g. unrelated, possibly related, etc.).

Time frame:
Up to 28 days post all treatment
Reported as:
Number · related events
Tolerability of Trial Therapy as Assessed by Adverse Event Reporting
related eventsOral Testosterone Undecanoate Followed by Enzalutamide as Therapy
Tolerability of Trial Therapy as Assessed by Adverse Event Reporting6
SecondaryTime to PSA Progression While on Enzalutamide

Number of weeks from start of enzalutamide treatment until PSA progression.

Time frame:
Up to 2 years post enzalutamide

Results for this outcome have not been posted.

SecondaryTime to PSA Progression While on Enzalutamide From Start of Oral Testosterone Therapy

Number of weeks from start of oral testosterone therapy until PSA progression while on enzalutamide treatment.

Time frame:
Up to 2 years post all treatment

Results for this outcome have not been posted.

Adverse events

Collected over from the start of treatment up to 2 years post treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy0/15 (0%)2/15 (13.3%)10/15 (66.7%)
Most frequent serious events
Most frequent serious events
EventOral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy
Back PainMusculoskeletal and connective tissue disorders1/15
Chest wall painMusculoskeletal and connective tissue disorders1/15
Most frequent other events
Showing 10 of 30
Most frequent other events
EventOral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy
HeadacheNervous system disorders3/15
FatigueGeneral disorders3/15
DiarrheaGastrointestinal disorders3/15
Urinary frequencyRenal and urinary disorders2/15
Flu like symptomsGeneral disorders2/15
Creatinine increasedInvestigations2/15
Back painMusculoskeletal and connective tissue disorders2/15
AnorexiaMetabolism and nutrition disorders2/15
VomitingGastrointestinal disorders1/15
Upper respiratory infectionInfections and infestations1/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Oral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy
<=18 years0
Between 18 and 65 years2
>=65 years10
Age, Continuous
Age, Continuous(years)Oral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy
Mean71.5 (60 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Oral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy
Female0
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy
Hispanic or Latino0
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White8
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Oral Testosterone Therapy Given Until Radiographic Progression Followed by Enzalutamide Therapy
United States12
08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Aug 2025, 40 months.

Results were first posted in Sep 2026, 1 year 1 month after primary completion.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 40 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2025 → Dec 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2021
First posted
Oct 18, 2021
StartActual
Mar 7, 2022
Primary completionActual
Aug 4, 2025
CompletionEst.
Dec 4, 2026was Aug 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Active, not recruiting
changed Sep 29, 2026
Results
Results posted
posted Sep 29, 2026
Study completion
Aug 4, 2025→Dec 4, 2026
Sep 29, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameObjective Response Rate of Oral Testosterone Undecanoate (CT Scan)Up to 2 years → Up to 2 years post Oral Testosterone
Sep 29, 2026
Documents
Secondary outcomes
5 edited, 7 time frame changed, 1 removed, 2 description edited
What changed in the outcomes
  • EditedPBMC Immunologic and metabolic phenotypeMetabolic PhenotypeTime frame: 2 years
  • EditedChange in Quality of Life as Assessed by theThe-FACIT-Fatigue QuestionnaireTime frame: 2 years → Up to 2 years post Oral Testosterone
  • EditedSafety of Trial Therapy as assessedAssessed by adverse event reportingAdverse Event ReportingTime frame: 2 years → Up to 28 days post all treatment
  • EditedTolerability of Trial Therapy as assessedAssessed by adverse event reportingAdverse Event ReportingTime frame: 2 years → Up to 28 days post all treatment
  • EditedTime to PSA Progression While on Enzalutamide fromFrom Start of Oral Testosterone TherapyTime frame: Up to 2 years → Up to 2 years post all treatment
  • RemovedPeak Testosterone LevelTime frame: At 4 hours post first dose
  • Time framePSA50 Response to Oral Testosterone Therapy2 years → Up to 2 years post Oral Testosterone
  • Time frameTime to PSA Progression While on Oral TestosteroneUp to 2 years → Up to 2 years post Oral Testosterone
  • Time frameTime to Clinical or Radiographic Progression While on Oral TestosteroneUp to 2 years → Up to 2 years post Oral Testosterone
  • Time framePSA50 Response to Enzalutamide Therapy2 years → Up to 2 years post Enzalutamide
  • Time frameObjective Response Rate of Enzalutamide Therapy (CT Scan)2 years → Up to 2 years post Enzalutamide
  • Time frameChange in Quality of Life as Assessed by the- Short Form 36 (SF-36) Questionnaire2 years → Up to 2 years post Oral Testosterone
  • Time frameTime to PSA Progression While on EnzalutamideUp to 2 years → Up to 2 years post enzalutamide
  • DescriptionTime to Clinical or Radiographic Progression While on Oral Testosterone: how it is measured was reworded
  • DescriptionTime to PSA Progression While on Oral Testosterone: how it is measured was reworded
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Completed→Active, not recruiting
    Results posted
    Study completion Aug 4, 2025→Dec 4, 2026
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameObjective Response Rate of Oral Testosterone Undecanoate (CT Scan)Up to 2 years → Up to 2 years post Oral Testosterone
    Secondary outcomes 5 edited, 7 time frame changed, 1 removed, 2 description edited
    What changed in the outcomes
    • EditedPBMC Immunologic and metabolic phenotypeMetabolic PhenotypeTime frame: 2 years
    • EditedChange in Quality of Life as Assessed by theThe-FACIT-Fatigue QuestionnaireTime frame: 2 years → Up to 2 years post Oral Testosterone
    • EditedSafety of Trial Therapy as assessedAssessed by adverse event reportingAdverse Event ReportingTime frame: 2 years → Up to 28 days post all treatment
    • EditedTolerability of Trial Therapy as assessedAssessed by adverse event reportingAdverse Event ReportingTime frame: 2 years → Up to 28 days post all treatment
    • EditedTime to PSA Progression While on Enzalutamide fromFrom Start of Oral Testosterone TherapyTime frame: Up to 2 years → Up to 2 years post all treatment
    • RemovedPeak Testosterone LevelTime frame: At 4 hours post first dose
    • Time framePSA50 Response to Oral Testosterone Therapy2 years → Up to 2 years post Oral Testosterone
    • Time frameTime to PSA Progression While on Oral TestosteroneUp to 2 years → Up to 2 years post Oral Testosterone
    • Time frameTime to Clinical or Radiographic Progression While on Oral TestosteroneUp to 2 years → Up to 2 years post Oral Testosterone
    • Time framePSA50 Response to Enzalutamide Therapy2 years → Up to 2 years post Enzalutamide
    • Time frameObjective Response Rate of Enzalutamide Therapy (CT Scan)2 years → Up to 2 years post Enzalutamide
    • Time frameChange in Quality of Life as Assessed by the- Short Form 36 (SF-36) Questionnaire2 years → Up to 2 years post Oral Testosterone
    • Time frameTime to PSA Progression While on EnzalutamideUp to 2 years → Up to 2 years post enzalutamide
    • DescriptionTime to Clinical or Radiographic Progression While on Oral Testosterone: how it is measured was reworded
    • DescriptionTime to PSA Progression While on Oral Testosterone: how it is measured was reworded
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05081193
Collaborators
Clarus Therapeutics, Inc., Allegheny Health Network
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Mar 7, 2022
Primary completion
Aug 4, 2025
Completion
Dec 4, 2026 (estimated)
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Samuel Denmeade, MD
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Testosterone undecanoate · Enzalutamide

Start the discussion